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Abstract
Complicated intra-abdominal infections are an important cause of morbidity and are frequently associated with
poor prognosis, particularly in higher risk patients.
Well defined evidence-based recommendations for intra-abdominal infections treatment are partially lacking
because of the limited number of randomized-controlled trials.
Factors consistently associated with poor outcomes in patients with intra-abdominal infections include increased
illness severity, failed source control, inadequate empiric antimicrobial therapy and healthcare-acquired infection.
Early prognostic evaluation of complicated intra-abdominal infections is important to select high-risk patients for
more aggressive therapeutic procedures.
The cornerstones in the management of complicated intra-abdominal infections are both source control and anti-
biotic therapy.
The timing and the adequacy of source control are the most important issues in the management of intra-abdom-
inal infections, because inadequate and late control of septic source may have a negative effect on the outcomes.
Recent advances in interventional and more aggressive techniques could significantly decrease the morbidity and
mortality of physiologically severe complicated intra-abdominal infections, even if these are still being debated and
are yet not validated by limited prospective trials.
Empiric antimicrobial therapy is nevertheless important in the overall management of intra-abdominal infections.
Inappropriate antibiotic therapy may result in poor patient outcomes and in the appearance of bacterial resistance.
Antimicrobial management is generally standardised and many regimens, either with monotherapy or combination
therapy, have proven their efficacy. Routine coverage especially against Enterococci and candida spp is not always
recommended, but can be useful in particular clinical conditions. A de escalation approach may be recommended
in patients with specific risk factors for multidrug resistant infections such as immunodeficiency and prolonged
antibacterial exposure.
Therapy should focus on the obtainment of adequate source control and adequate use of antimicrobial therapy
dictated by individual patient risk factors. Other critical issues remain debated and more controversies are still open
mainly because of the limited number of randomized controlled trials.
Introduction
Intra-abdominal infections (IAI) include many patholo-
gical conditions, ranging from uncomplicated appendici-
tis to faecal peritonitis. IAI are classified into
uncomplicated and complicated [1].
In uncomplicated IAIs the infectious process only
involves a single organ and does not proceed to perito-
neum. Patients with such infections can be managed
with either surgical resection alone, or with antibiotics
alone. When the focus of infection is treated effectively
by surgical excision, 24 hours perioperative prophylaxis
is sufficient. Patients with intra-abdominal infection,
including acute diverticulitis and certain forms of acute
appendicitis, may be managed nonoperatively.
In complicated IAIs, the infectious process proceeds
beyond the organ, and causes either localized peritonitis
or diffuse peritonitis. The treatment of patients with
complicated intra-abdominal infections involves both
source control and antibiotic therapy.
Complicated intra-abdominal infections represent an
important cause of morbidity and are frequently asso-
ciated with poor prognosis.
Peritonitis is classified into primary, secondary or ter-
tiary peritonitis [2]. Correspondence: m.sartelli@virgilio.it
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out loss of integrity of the gastrointestinal tract. It is
rare. It mainly occurs in infancy and early childhood
and in cirrhotic patients.
Secondary peritonitis, the most common form of peri-
tonitis, is an acute peritoneal infection resulting from
loss of integrity of the gastrointestinal tract or from
infected viscera. It is caused by perforation of the gas-
trointestinal tract (e.g. perforated duodenal ulcer) by
direct invasion from infected intra-abdominal viscera
(e.g. gangrenous appendicitis). Anastomotic dehiscences
are common causes of peritonitis in the postoperative
period.
Tertiary peritonitis is a recurrent infection of the peri-
toneal cavity that follows either primary or secondary
peritonitis.
Mortality rates associated with secondary peritonitis
with severe sepsis or septic shock have reported an aver-
age mortality of approximately 30% [3-5].
Intra-abdominal infections are also classified into
community-acquired intra-abdominal infections (CA-
IAIs) and healthcare-acquired intra-abdominal infections
(HA-IAIs). CA-IAIs are acquired in community, HA-
IAIs develop in hospitalized patients or residents of
long-term care facilities. They are characterized by
increased mortality because of both underlying patient
health status and increased likelihood of infection
caused by multi drugs resistant organisms [6].
Prognostic evaluation
Early prognostic evaluation of complicated intra-abdom-
inal infections is important to assess the severity and
the prognosis of the disease.
Factors influencing the prognosis of patients with
complicated intra-abdominal infections include
advanced age, poor nutrition, pre-existing diseases,
immunodepression, extended peritonitis, occurrence of
septic shock, poor source control, organ failures, pro-
longed hospitalization before therapy, and infection with
nosocomial pathogens [7-14].
Scoring systems can be broadly divided into two
groups: disease-independent scores for evaluation of ser-
ious patients requiring care in the intensive care unit
(ICU) such as APACHE II and Simplified Acute Physiol-
ogy Score (SAPS II) and peritonitis-specific scores such
as MPI [8].
Although previously considered a good marker,
APACHE II value in peritonitis has been questioned
because of the APACHE II impossibility to evaluate
interventions, despite the fact that interventions might
significantly alter many of the physiological variables
[15]. The MPI is specific for peritonitis and easy to cal-
culate, even during surgery. MPI is calculated using sim-
ple factors such as degree of peritonitis, age, sex, time
from perforation to operation, origin of sepsis, kind of
exudates (clear, purulent or faecal).
Billing et al. [16] demonstrated the reliability of MPI
in 2003 patients from 7 centres in Europe. With a
threshold index score of 26, the sensitivity was 86
(range 54-98) per cent, specificity 74 (range 58-97) per
cent and accuracy 83 (range 70-94) per cent in predict-
ing death. For patients with a score less than 21 the
mean mortality rate was 2.3 (range 0-11) per cent, for
score 21-29 22.5 (range 10.6-50) per cent and for score
greater than 29 59.1 (range 41-87) per cent. In this
study the Mannheim peritonitis index provided an easy
and reliable means of risk evaluation and classification
for patients with peritoneal inflammation.
In 2008 Panhofer et al. [17] published a retrospective
single-centre cohort study in patients who developed
tertiary peritonitis, proposing a combination of both
MPI and APACHE II, concluding that combination of
prognostic scores was very useful to detect tertiary
peritonitis.
Hypothesizing that intrinsic risk factors were a better
predictor of mortality rather than the type of infection,
Inui at al. [18] recently investigated the utility of Charl-
son Comorbidity Index and multiple organ dysfunction
(MOD). They reviewed retrospectively 452 patients with
IAI who had been treated over 8 years (June 1999-June
2007). Charlson Comorbidity Index and Multiple Organ
Dysfunction (MOD) scores were evaluated at admission
and on postoperative day 7. When patients with appen-
dicitis were excluded, there was no difference in mortal-
ity or complications betweenp a t i e n t sw i t hC A - I A Ia n d
HA-IAI. Statistical analysis demonstrated that catheter-
related bloodstream infection, cardiac event, and age >
or = 65 were independent risk factors for mortality.
Among patients who failed initial therapy, a non-appen-
diceal source of infection and a Charlson score > or = 2
were determined to be independent risk factors. Non-
appendiceal source of infection and MOD score > or =
4 on postoperative day 7 were found to be independent
predictors for re-intervention.
Diagnosis
In the patient with abdominal sepsis early detection and
treatment is essential to minimize complications [19].
Complicated intra-abdominal infections diagnosis is
mainly a clinical diagnosis.
Abdominal pain, which may be acute or insidious.
Initially, the pain may be dull and poorly localized (visc-
eral peritoneum) and often progresses to steady, severe,
and more localized pain (parietal peritoneum).
Systemic manifestations are SIRS manifestations: Core
body temperature > 38°C or < 36°C, heart rate > 90
beats per minute, respiratory rate > 20 breaths per min-
ute (not ventilated) or PaCO2 < 32 mm Hg (ventilated),
Sartelli World Journal of Emergency Surgery 2010, 5:9
http://www.wjes.org/content/5/1/9
Page 2 of 20WBC > 12,000, < 4,000 or > 10% immature forms
(bands) [20].
Hypotension and hypoperfusion signs such as lactic
acidosis, oliguria, and acute alteration of mental status
are indicative of evolution to severe sepsis.
Abdominal rigidity suggests peritonitis and the need
for urgent laparotomy.
The diagnostic approach to confirm abdominal infec-
tion source in septic patients depends on the hemo-
dynamic stability of the patient.
Unstable Patients may not perform studies that
require trips away from the ICU or emergency depart-
ment [19]. In these patients intra-abdominal septic
source may be detected by ultrasound (US).
Abdominal ultrasound, that has the advantage of being
portable, may be helpful in the evaluation of right upper
quadrant (e.g. perihepatic abscess, cholecystitis, pancrea-
titis), right lower quadrant, and pelvic pathology (e.g.
appendicitis, tubo-ovarian abscess, Douglas abscess), but
the examination is sometimes limited because of patient
discomfort, abdominal distension, and bowel gas inter-
ference [21].
When patients are stable, computerized tomography
(CT) is the imaging modality of choice for most intra-
abdominal processes [22].
Computed tomography (CT) of the abdomen and the
pelvis, when it is possible to perform it, remains the
diagnostic study of choice for intra-abdominal infec-
tions. CT can detect small quantities of fluid, areas of
inflammation, and other GI tract pathology, with a very
high sensitivity [23].
The value of both CT and US in the diagnostic work-
up for intra-abdominal infections has been fully studied
in relation to acute appendicitis. A meta-analysis by
Doria et al. [24] evaluated the diagnostic performance of
ultrasonography (US) and computed tomography (CT)
for the diagnosis of appendicitis in pediatric and adult
populations. This meta-analysis found that pooled sensi-
tivity and specificity for diagnosis of appendicitis in chil-
dren were 88% and 94%, respectively, for ultrasound
studies and 94% and 95%, respectively, for CT studies.
Pooled sensitivity and specificity for diagnosis in adults
were 83% and 93%, respectively, for ultrasound studies
and 94% and 94%, respectively, for CT studies.
From the diagnostic performance perspective, CT has
a significantly higher sensitivity than US in studies of
children and adults; from the safety perspective, how-
ever, the radiation associated with CT, especially in chil-
dren, should be always considered.
An option in the diagnosis of critically ill patients in
ICU is bedside diagnostic laparoscopy. It avoids patient
transport, is may be very accurate, and maintains ICU
monitoring. Bedside diagnostic laparoscopy for intraab-
dominal diseases has high diagnostic accuracy and in
unstable patients with abdominal sepsis of unknown ori-
gin, it may be regarded as a good diagnostic [25].
Laparoscopy is gaining wider acceptance in emergency
surgery [26]. Diagnostic laparoscopy is widely used to
identify the causative pathology of acute abdominal
pain. It may also be followed by laparoscopic treatment
of the detected abdominal disorder [27,28].
The accuracy of diagnostic laparoscopy is very high. In
the last years studies have reported definitive diagnosis
rates of between 86-100% in unselected patients [29-31].
Diagnostic laparoscopy is very important especially in
patients with pelvic disease and suspected appendicitis.
In cases of uncertain preoperative diagnosis in septic
and unstable patients, laparoscopy can shorten the
observation period and avoid the need for imaging test
[27].
Source control
Source control encompasses all measures undertaken to
eliminate the source of infection and to control ongoing
contamination.
The most common source of infection in community
acquired intra-abdominal infections is the appendix, fol-
lowed by the colon, and then the stomach. Dehiscences
complicate 5-10% of intra-abdominal bowel anasto-
moses, and are associated with a mortality increase [3].
Timing and adequacy of source control are the most
important issues in the management of intra-abdominal
infections, because inadequate and late operation may
have a negative effect on the outcome.
E a r l yc o n t r o lo ft h es e p t i cs o u r c ec a nb ea c h i e v e d
either by nonoperative or operative means.
Nonoperative interventional procedures include percu-
taneous drainages of abscesses.
Ultrasound and CT guided percutaneous drainage of
abdominal and extraperitoneal abscesses in selected
patients are safe and effective. Numerous studies in the
s u r g e r ya n dr a d i o l o g yl i t e r a t u r eh a v ed o c u m e n t e dt h e
effectiveness of percutaneous drainage in selected
patients, with cure rates of 62%-91% and with morbidity
and mortality rates equivalent to those of surgical drai-
nage [32-39].
The principal cause for failure of percutaneous drai-
nage is misdiagnosis of the magnitude, extent, complex-
ity, location of the abscess [40].
Surgery is the most important therapeutic measure to
control intra-abdominal infections.
Generally, the choice of the procedure depends on the
anatomical source of infection, on the degree of perito-
neal inflammation, on the generalized septic response
and on the patient’s general conditions.
Surgical source control entails resection or suture of a
diseased or perforated viscus (e.g. diverticular perfora-
tion, gastroduodenal perforation), removal of the
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of necrotic tissue, resection of ischemic bowel and
repair/resection of traumatic perforations.
Laparotomy is usually performed through a midline
incision.
The objectives are both to establish the cause of peri-
tonitis and to control the origin of sepsis.
Appendicitis
Acute appendicitis is the most common intra-abdominal
condition requiring emergency surgery.
Acute appendicitis is the most common intra-abdom-
inal condition requiring emergency surgery. Studies
have demonstrated that antibiotics alone may be useful
to treat patients with early, non perforated appendicitis,
even if there is a risk of recurrence [41].
In 1995, Eriksson and Granstrom [42] published the
results of a randomized trial of antibiotics versus surgery
in the treatment of appendicitis. All patients treated
conservatively were discharged within 2 days, except
one who required surgery because of peritonitis second-
ary to perforated appendicitis. 14% of patients treated
conservatively were readmitted within 1 year as a result
of recurrent appendicitis and underwent surgery, when
appendicitis was confirmed.
In 2006 Styrud et al. [43] published the results of a
Swedish multicenter randomized trial. In the antibiotic
group 86% improved without surgery; a rate of 14% of
patients was operated on within 24 hours, and the diag-
nosis of acute appendicitis was confirmed in all but one
patient, and he was suffering from terminal ileitis; 5% of
patients had a perforated appendix in this group. The
recurrence rate of symptoms of appendicitis among the
patients treated with antibiotics was 14% during the 1-
year follow-up.
Recently a further randomized clinical trial by Hanson
et al. [44] compared antibiotic therapy versus appen-
dectomy as primary treatment of acute appendicitis.
Treatment efficacy was 90.8% for antibiotic therapy and
89.2 per cent for surgery. Recurrent appendicitis
occurred in 13.9% of patients treated conservatively after
a median of 1 year.
Although antibiotics may be used as primary treat-
ment for selected patients with suspected uncomplicated
appendicitis, appendectomy is still the gold standard
therapy for acute appendicitis.
The advent of minimally invasive surgery has modified
the surgical treatment of acute appendicitis and a lot of
prospective randomized studies, meta-analyses, and sys-
tematic critical reviews have been published on the
topic of laparoscopic appendectomy. Laparoscopic
appendectomy is safe and effective, but open surgery
still conferres benefits, in particular with regards to the
likelihood of postoperative intra-abdominal abscess.
In 2007 a meta-analysis of 34 studies comparing
laparoscopic appendectomy with open appendectomy
was published by Bennett et al. [45]. The meta-analysis
confirmed the findings of fewer surgical site infections
and shorter hospitalization with laparoscopic appendect-
omy. Intra-abdominal abscesses were more common
with laparoscopic appendectomy.
Although appendix abscess occurs in 10% of patients
with acute appendicitis, its surgical management is sur-
rounded with controversy. The traditional management
of appendiceal mass has been initial conservative treat-
ment followed by interval appendicectomy. Recently
interval appendicectomy has been questioned, and there
is much controversy whether interval appendicectomy is
appropriate for adults with an appendiceal abscess. The
main debate is based on the recurrence rate, the compli-
cation rate of interval appendicectomy, and the potential
for underlying malignancy [46]. The results of a review
by Andersonn and Petzold [47], based mainly on retro-
spective studies, supported the practice of nonsurgical
treatment without interval appendectomy in patients
with appendiceal abscess or phlegmon.
In 2007 another review [48] on management of appen-
diceal mass demonstrated that conservative management
approach was successful in the majority of patients pre-
senting with an appendix mass. The Authors concluded
that after initial successful conservative management,
routine use of interval appendicectomy was not justified
in asymptomatic patients.
Diverticulitis
Sigmoid diverticulitis is a common disease of the Wes-
tern World and results in a significant number of hospi-
tal admissions.
Antibiotics are the standard of care for uncomplicated
diverticulitis.
Percutaneous drainage is the intervention of choice for
simple uniloculated abscesses. It has a success rate of
more than 80%, but it may haveah i g hf a i l u r er a t ei n
cases of complex multiloculated or inaccessible
abscesses [49].
The use of antibiotics and percutaneous drainage in
the management of diverticular abscesses facilitates sin-
gle stage operation to perform subsequently an elective
sigmoidectomy.
Ambrosetti et al. [50] studied retrospectively 73
patients with diverticular abscesses with a follow up of
43 months and found that 59% of the patients needed
surgery either during the acute admission or as an elec-
tive procedure. The other patients did not need surgical
intervention after conservative treatment either with or
without percutaneous drainage. The study also com-
pared the mesocolic abscesses with the pelvic ones. Pel-
vic abscesses exhibited an aggressive behaviour and
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and were likely to require surgery.
Brandt et al. [51] retrospectively compared patients
with CT confirmed abscesses, treated by antibiotics
alone and patient treated by antibiotics with percuta-
neous drainage. The patients treated with antibiotics
alone achieved an outcome similar to patients treated
with percutaneous drainage. The average abscess size
was 4 cm in the antibiotic only group and 6 cm in per-
cutaneous group. Failure rate of percutaneous drainage
in this series was 33%.
Siewert et al. [52] reported that antibiotics alone were
effective in resolving acute symptoms for abscess size
less than 3 cm.
Urgent surgery for colonic diverticula perforations is
indicated in patients with large or/and multiloculated
diverticular abscesses inaccessible to percutaneous drai-
nage or in whom clinical symptoms persist after CT
guided percutaneous drainage, diverticulitis associated
with free perforation and purulent or fecal diffuse
peritonitis.
There is still controversy about the optimal surgical
management of colonic diverticular disease, complicated
by peritonitis.
Hartmann’s resection has been considered the proce-
dure of choice in patients with generalized peritonitis
and remains a safe technique for emergency colectomy
in perforated diverticulitis, especially in elderly patients
with multiple co-morbidities [53]. More recently, some
reports have suggested that primary resection and ana-
stomosis is the preferred approach to diverticulitis, even
in the presence of diffuse peritonitis [54,55].
In 2006 a sistematic review by Constantinides et al.
[56] about primary resection with anastomosis vs. Hart-
mann’s procedure in nonelective surgery for acute colo-
nic diverticulitis was published. Patients selected for
primary resection and anastomosis had a lower mortality
than those treated with Hartmann’s procedure in the
emergency setting and comparable mortality under con-
ditions of generalized peritonitis. This analysis high-
lighted the need for high-quality randomized trials
comparing the two techniques.
Emergency laparoscopic resection in complicated
diverticular disease is feasible and safe and may be per-
formed by expert surgeons without additional morbidity
and mortality [57,58]. In 2009 a randomized multicenter
trial on laparoscopic sigmoid resection for diverticulitis
was published [59]. In this trial patients with sympto-
matic diverticulitis of the sigmoid colon were rando-
mized to either laparoscopic sigmoid resections or open
sigmoid resections. The laparoscopic sigmoid resection
was associated with a 15.4% reduction in major compli-
cation rates, less pain, improved quality of life, and
shorter hospitalization at the cost of a longer operating
time.
In high risk patients, a laparoscopic approach may be
used for exploration and peritoneal lavage and drainage
[60,61].
Gastroduodenal perforations
Gastroduodenal perforations have decreased significantly
in the last years thanks to the widespread adoption of
medical therapies for peptic ulcer disease and stress
ulcer prophylaxis among critically ill patients. Successful
laparoscopic repair of perforated gastric and duodenal
ulcers has been reported but the technique has yet to be
universally accepted [62].
A systematic review was published in 2005 [63] in
order to measure the effect of laparoscopic surgical
treatment versus open surgical treatment in patients
with a diagnosis of perforated peptic ulcer. Two rando-
mised clinical trials, which were of acceptable quality,
were included. No statistically significant differences
between laparoscopic and open surgery in the propor-
tion of abdominal septic complications, pulmonary com-
plications or actual number of septic abdominal
complications were found. With the information pro-
vided by the available clinical trials, laparoscopic surgery
results were not clinically different from those of open
surgery. This systematic review suggested that it was
necessary to develop more randomised controlled trials
with a greater number of patients.
The spontaneous perforation of gastric cancer is a rare
fatal complication, occurring in 1% of patients with gas-
tric cancer, and it has a wide hospital mortality range
(0-82%). It has been also reported that about 10-16% of
all gastric perforations are caused by gastric carcinoma
[64]. In order to evaluate the gastric perforations and
improve an alternative pathway for the management of
this disorder without an available pathologist a study
was realized by Ergul et al. [64]. The Authors recorded
513 patients who had undergone surgical treatment for
gastric perforation due to gastric ulcus or gastric carci-
noma in two medical centers. According to the results
of their analysis patients age more than 60 years, an
ulcus diameter (with edema) more than 6 cm, a perfora-
tion diameter more than 0.5 cm, a symptom duration of
more than 20 h, and a white blood cell count less than
15.10(3)/microL, suggested for a gastric carcinoma. This
system had a specificity of 98.7%, a sensitivity of 53.7%,
an e g a t i v ep r e d i c t e dv a l u eo f9 3 . 4 % ,a n dp o s i t i v ep r e -
dicted value of 85.7%. They concluded that diagnosis of
malignancy was often made only on postoperative or
operative frozen pathologic examination. They suggested
a new pathway for the gastric perforations, if a patholo-
gist was not available during the operation.
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Small bowel perforations are a less common source of
peritonitis in the Western countries than the Eastern
ones. Most small intestinal perforations are due to
unrecognized intestinal ischemia. Treatment is most
commonly resection of the involved segment. Small
bowel obstruction has previously been considered a rela-
tive contraindication for laparoscopic management. A
literature search of the Medline database by Ghosheh et
al. [65] defined the outcome of laparoscopy for acute
small bowel obstruction. Nineteen studies from between
1994 and 2005 were identified. The most common etiol-
ogies of obstruction were adhesions (83.2%), abdominal
wall hernia (3.1%), malignancy (2.9%), internal hernia
(1.9%), and bezoars (0.8%). Laparoscopic treatment was
possible in 705 cases with a conversion rate to open sur-
gery of 33.5%. Causes of conversion were dense adhe-
sions (27.7%), the need for bowel resection (23.1%),
unidentified etiology (13.0%), iatrogenic injury (10.2%),
malignancy (7.4%), inadequate visualization (4.2%), her-
nia (3.2%), and other causes (11.1%). Morbidity was
15.5% (152/981) and mortality was 1.5% (16/1046).
There were 45 reported recognized intraoperative
enterotomies (6.5%), but less than half resulted in con-
version. The Authors concluded that laparoscopy was
an effective procedure for the treatment of acute small
bowel obstruction with acceptable risk of morbidity and
early recurrence
In eastern countries small bowel perforations usually
arise on a background of enteric fever. These typhoid
ileal perforations have a mort a l i t yr a t eu pt o6 0 %[ 6 6 ] .
Early surgery is associated with a better outcome. A lot
of surgical procedures have been described in these per-
forations such as simple closure, wedge excision or seg-
mental resection and anastomosis, ileostomy and side to
side ileo-transverse anastomosis after primary repair of
the perforation [66].
Also primary intestinal tuberculosis is uncommon in
European and North American countries and more
common in Eastern countries. Most common site of
extra pulmonary tuberculosis is the ileocaecal region
and terminal ileum [67]. The most common complica-
tion of small bowel tuberculosis is obstruction due to
the narrowing of the lumen by hyper plastic ileocaecal
tuberculosis or stricture of small intestine and perfora-
tion in ulcerative type of tuberculosis, which are com-
monly multiple. Treatment of tubercular perforation of
ileum depends upon the condition of the gut, general
condition of the patient and number of perforation.
Because of high mortality rate, the resection of the
affected area and anastomosis may be the treatment of
choice rather than primary closure [68].
Cholecystitis
Laparoscopic cholecystectomy versus open cholecystect-
omy question has been extensively investigated. Begin-
ning in the early 1990s, techniques and indications for
laparoscopic management of the acutely inflamed gall-
bladder were discussed and laparoscopic cholecystect-
omy is now accepted as being safe for acute
cholecystitis. Compared with delayed laparoscopic chole-
cystectomy, early laparoscopic cholecystectomy for acute
cholecystitis is safer and shows lower rates of conver-
sions than delay laparoscopic cholecystectomy. Several
studies showed that early laparoscopic cholecystectomy
resulted in a significantly reduced length of stay, no
major complications, and no significant difference in
conversion rates when compared with initial antibiotic
treatment and delayed laparoscopic cholecystectomy
[69-72].
In 2009 a prospective trial by González-Rodríguez et
al. [73] about early or delayed laparoscopic cholecystect-
omy in acute cholecystitis confirmed that there is no
advantage in delaying cholecystectomy for acute chole-
cystitis on the basis of complications, rate of conversion
to open surgery, and mean hospital stay. Thus, early
cholecystectomy should be the preferred surgical
approach for patients with acute lithiasic cholecystitis.
Despite the evidence, early laparoscopic cholecystect-
omy is not the most common treatment for acute chole-
cystitis in practise and wrongly it remains common
practice to treat acute cholecystitis with intravenous
antibiotic therapy and interval laparoscopic cholecystect-
omy preferentially [74].
Surgical options in patients with severe intra-abdominal
infections
Patients with severe sepsis or septic shock may be com-
plicated by high mortality rates. They may benefit of
aggressive surgical treatment to control multiple organ
dysfunction syndrome caused by ongoing intra-abdom-
inal infection.
The surgical treatment strategies following an initial
emergency laparotomy may include either a relaparot-
omy, only when the patient’s condition demands it
("relaparotomy on-demand”), or a planned relaparotomy
after 36-48 hours with temporarily abdomen closure or
open abdomen.
The aim in the on-demand laparotomy is to perform
reoperation only in those patients who may benefit from it.
The selection of the patients for relaparotomy is diffi-
cult and is based on clinical judgments with individual
variability among surgeons. Currently, there is no con-
sensus on which criteria may be used to undergo rela-
parotomy [75-80]
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sidered important in their decisional process of patient
selection for relaparotomy Van Ruler et al. [75] pub-
lished in 2008 the results of a questionnaire. Surgeons
were asked to rank the importance of 21 clinical vari-
ables on their decision whether or not to reoperate in a
patient with secondary peritonitis. Of variables labeled
important only, a diffuse extent of abdominal contami-
nation, localization of the infectious focus (upper gastro-
intestinal tract including small bowel), and both low and
high leukocyte counts independently predicted positive
relaparotomy. These variables had only moderate pre-
dictive accuracy. The results of the questionnaire
demonstrated that there was no consensus among sur-
geons which variables were important in decision mak-
ing for relaparotomy.
Over the past years, also Procalcitonin (PCT) was
investigated as a laboratory variable to select patients for
relaparotomy. Recently a study by Novotny et al. [81]
evaluated procalcitonin (PCT) as a parameter for early
detection of progressing sepsis after operative treatment
of the infective source. PCT ratio appeared to be a valu-
able aid in deciding if further relaparotomies were
necessary after initial operative treatment of an intraab-
dominal septic focus.
The final decision to perform a reoperation on a
patient in the on-demand setting is generally based on
patients generalized septic response and lack of clinical
improvement.
The aim in the planned laparotomy is to perform
every 36 to 48 hours inspection, drainage, and peritoneal
lavage of the abdominal cavity. It is performed either
with temporarily abdomen closure or open abdomen.
Surgical approach that leaves the abdomen open may
both facilitate reexploration and prevent deleterious
effects of abdominal compartment syndrome (ACS) [82].
In septic shock fluids infusion during resuscitation and
their accumulation, bowel edema, and forced closure of
the abdominal wall cause intra-abdominal hypertension
(IAH) and consequently modify pulmonary, cardiovascu-
lar, renal, splanchnic, and central nervous system phy-
siology causing significant morbidity and mortality.
Open treatment was introduced for the management
of severe intra-abdominal infection and pancreatic
necrosis some years ago [83]. However, severe complica-
tions such as evisceration, fistula formation, and the
development of giant incisional hernias were observed.
Therefore, the technique of open treatment was modi-
fied, leading to the concept of “covered laparostomy”
[84-86]. Temporary closure of the abdomen may be
achieved using gauze and large, impermeable, self-adhe-
sive membrane dressings, absorbable meshes, nonab-
sorbable meshes, zippers and vacuum-assisted closure
(VAC) devices. Vacuum-assisted fascial closure (VAC)
has become an option for the treatment of open abdo-
men [87-90].
Some studies described open abdomen approach in
the patients with severe sepsis or septic shock [91-94].
Some studies have indicated that the planned strategy
increases the risk of multiple organ failure because it
amplifies the systemic inflammatory response by multi-
ple surgical lavages, leading to increased mortality
[95,96], morbidity, ICU stays, and hospital stays [97].
In 2007 van Ruler et al. [98] published a randomized,
clinical trial comparing on-Demand vs Planned Relapar-
otomy strategy in patients with severe peritonitis. The
patients in the on-demand relaparotomy group did not
have a significantly lower rate of death or major peritoni-
tis-related morbidity compared with the planned relapar-
otomy group but did have a substantial reduction in
relaparotomies, health care utilization, and medical costs.
In 2007 a randomised study by Robledo et al. [99]
compared open with closed “on demand” management
of severe peritonitis. The study however was interrupted
after the inclusion of 40 patients because of a high rate
of mortality for the open abdomen group (55 vs 30%).
The “open abdomen” was managed with only a non-
absorbable polypropylene mesh.
Antimicrobial therapy in Intra-abdominal
Infections
Antimicrobial therapy plays an integral role in the man-
agement of intra-abdominal infections. The choice of an
inadequate antimicrobial agent is a cause of therapeutic
failure.
Complicated intra-abdominal infections are predomi-
nantly related to bowel perforation and contamination
with its flora. The microbial etiology depends on the
level of disruption of the gastrointestinal tract.
Microbiology
The upper gastrointestinal tract (stomach, duodenum,
jejunum, and upper ileum) contains relatively few
microorganisms, less than 103 to 105 bacteria/mL.
I n f e c t i o n sd e r i v e df r o mt h es t o m a c h ,d u o d e n u m ,a n d
proximal small bowel can be caused by gram-positive
and gram-negative aerobic and facultative organisms.
The lower gastrointestinal tract contains hundreds of
bacterial species, and concentrations of 1011-13 bac-
teria/mL.
Infections derived from distal ileum perforations can
be caused by gram-negative facultative and aerobic
organisms with variable density.
Colon-derived intra-abdominal infections can be
caused by facultative and obligate anaerobic organisms,
gram-negative facultative organism (Enterobacteriaceae
with E. coli at the first place), other gram-negative
bacilli and Enterococci.
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aerobes. With the exception of Bacteroides spp., most
other anaerobes are the main barrier against coloniza-
tion and infection by other pathogens.
The medical antecedents of the patient can affect the
normal flora. In particular, patients hospitalised may be
colonized by altered flora including multidrug-resistant
nosocomial pathogens or Candida spp.
Microbiological specimens
Once the diagnosis of complicated intra-abdominal
infection is suspected, it is appropriate to begin empiric
antimicrobial therapy before an exact diagnosis is estab-
lished and before results of appropriate cultures are
available.
The role of microbiologic workup of infected fluid has
been debated in the last years.
Since the causative pathogens can easily be predicted
in community acquired infections, bacteriological diag-
nosis is not necessary. The absence of impact of bacter-
iological cultures has been well documented, especially
in appendicitis as the etiologic agents causing peritonitis
are highly predictable and effective broad-spectrum anti-
biotic therapy is available.
In a prospective study, Gladman et al. [100] followed
721 consecutive appendicectomies. Swabs were per-
formed in 463 cases. The culture was positive in 113
with the identification of 11 resistant microorganisms.
Overall, 39 patients (5%) developed significant post-
operative infective complications. Neither the presence
of a positive intra-operative culture, nor the isolation of
resistant organisms were significant in predicting infec-
tive complications. The authors concluded that the
results of intra-operative culture did not influence clini-
cal outcome in patients undergoing appendicectomy.
The practice of taking routine microbiological swabs for
culture had to be seriously questioned in patients under-
going appendicectomy
For higher-risk patients, cultures from the site of
infection should be always obtained, Cultures should be
performed from 1 specimen, provided it is of sufficient
volume (at least 1 mL of fluid or tissue, preferably
more). It should be transported to the laboratory in an
appropriate transport system.
Antimicrobial prophylaxis
Routine use of antimicrobial therapy is not appropriate
for all patients with intra-abdominal infections.
In uncomplicated IAIs, when the focus of infection is
treated effectively by surgical excision of the involved
tissue, the administration of antibiotics is unnecessary
beyond prophylaxis. Patients with an infected focus that
can be eradicated effectively by surgical intervention can
potentially be treated only with 24 hours antimicrobial
prophylaxis. Antimicrobial prophylactic agents are indi-
cated for patients with acute unperforated appendicitis
or cholecystitis that are surgically removed [101].
Antibiotic prophylaxis is also sufficient for the patients
with bowel necrosis due to a vascular accident or stran-
gulating bowel obstruction, in whom there is no evi-
dence of perforation or infected peritoneal fluid, for
those with gastroduodenal perforations operated within
24 hours in the absence of antacid therapy or malignant
disease, and for those with traumatic or iatrogenic
bowel injury repaired within 12 hours [101].
Risk stratification
Patients with intra-abdominal infections are generally
classified into low risk and high risk.
The definition of “risk” in intra-abdominal infections
remains vague. “High risk” is generally intended to
describe patients with a high risk for treatment failure.
In these patients intra-abdominal infections may be
associated with a high risk of isolation of resistant
pathogens from the intra-abdominal source. Effective
management of high risk patients requires the early use
of appropriate, broad-spectrum empirical antimicrobial
therapy.
The stratification of the patient’sr i s ki si m p o r t a n tt o
optimize the antibiotic treatment plan.
The increased mortality associated with inappropriate
empiric antibiotic therapy cannot be reversed by subse-
quent modifications. Therefore knowledge of patient’s
risk is essential to begin treatment as soon as possible
with the most appropriate regimen.
Many factors can contribute to a patient’s risk for iso-
lation of resistant pathogens. These include [102,103]:
￿ Health care-associated infections
￿ High severity of illness (APACHE II score >15)
￿ Advanced age
￿ Comorbidity and degree of organ dysfunction
￿ Poor nutritional status and low albumin level
￿ Immunodepression
￿ Presence of malignancy
In high risk patients the normal flora may be modified
and intra-abdominal infections may be caused by several
unexpected pathogens and by more resistant flora,
which may include, methicillin-resistant Staphylococcus
aureus, Enterococci, Pseudomonas aeruginosa, extended-
spectrum b-lactamases producing Enterobacteriaceae
(ESBLs) and Candida spp. In these infections antimicro-
bial regimens with broader spectrum of activity are
recommended, because adequate empirical therapy
appears to be important in reducing mortality.
Health care-associated infections are commonly
caused by more resistant flora, and for these infections,
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Although transmission of multidrug resistant organisms
is most frequently documented in acute care facilities,
all healthcare settings are affected by the emergence and
transmission of antimicrobial-resistant microbes.
Among intra-abdominal infections post-operative peri-
tonitis is a life-threatening infection and carries a high
risk of complications and mortality.
In order to describe the clinical, microbiological and
resistance profiles of community-acquired and nosoco-
mial intra-abdominal infections a prospective, observa-
tional study (EBIIA) [104] was completed in French.
The results or this study were published in 2009. From
January to July 2005, patients undergoing surgery/inter-
ventional drainage for IAIs with a positive microbiologi-
cal culture were included by 25 French centres. The
principal results of EBIIA were a higher diversity of
microorganisms isolated in nosocomial infections and
decreased susceptibility among these strains.
In order to assess the microbiological differences, par-
ticularly with respect to the type of bacteria recovered
and the level of antimicrobial susceptibility between
community-acquired and nosocomial IAIs, the results of
an interesting prospective observational study were pub-
lished by Seguin et al. [105] in 2006. Community-
acquired peritonitis accounted for 44 cases and nosoco-
mial peritonitis for 49 cases (post-operative in 35 cases).
In univariate analysis, the presence of MDR bacteria was
associated significantly with preoperative and total hos-
pital lengths of stay, previous use of antimicrobial ther-
apy, and post-operative antimicrobial therapy duration
and modifications. A 5-day cut-off in length of hospital
stay had the best specificity (58%) and sensitivity (93%)
for predicting whether MDR bacteria were present. In
multivariate analysis, only a composite variable associat-
ing pre-operative hospital length of stay and previous
use of antimicrobial therapy was a significant indepen-
dent risk-factor for infection with MDR bacteria. The
Authors concluded that the knowledge of these two fac-
t o r sm i g h tp r o v i d eam o r er a t i o n a lb a s i sf o rs e l e c t i n g
initial antimicrobial therapy for patients with compli-
cated intra-abdominal infections. In order to investigate
patient characteristics associated with a high risk of iso-
lation of resistant pathogens from an intra-abdominal
source, the results of a retrospective study by Swenson
et al. [106] were published recently. Complicated intra-
abdominal and abdominal organ/space surgical site
infections treated over a ten-year period in a single hos-
pital were studied. A total of 2,049 intra-abdominal
infections were treated during the period of study, of
which 1,182 had valid microbiological data. Health care
association, corticosteroid use, organ transplantation,
liver disease, pulmonary disease, and a duodenal source
all were associated with resistant pathogens.
Low risk patients are generally those with community-
acquired infections without risk factors. Intra-abdominal
infections in low risk patients are associated with
expected pathogens with known susceptibilities. Empiri-
cal agents in these patients must be directed at provid-
ing reliable activity against E coli, other gram negative
facultative bacteria, and B fragilis. Antibiotic regimens
with a broader spectrum of activity are not recom-
mended for low risk patients with intra-abdominal infec-
tions, because such regimens may carry a greater risk of
toxicity and facilitate acquisition of more resistant
organisms.
Antimicrobial regimens
Intra-abdominal infections may be managed with either
single or multiple antimicrobial regimens.
Recently the new guidelines for the management of
complicated intra-abdominal infections by the Surgical
Infection Society and the Infectious Diseases Society of
America were published [103].
According to the guidelines, for adults with extra-bili-
ary mild-to-moderate severity community acquired com-
plicated infections, the use of ticarcillin-clavulanate,
cefoxitin, ertapenem, moxifloxacin, or tigecycline as sin-
gle-agent therapy or combinations of metronidazole
with cefazolin, cefuroxime, ceftriaxone, cefotaxime, levo-
floxacin, or ciprofloxacin are recommended [103].
For adults with extra-biliary high severity complicated
infections, meropenem, imipenem-cilastatin, doripenem,
piperacillin/tazobactam, ciprofloxacin or levofloxacin in
combination with metronidazole, or ceftazidime or cefe-
pime in combination with metronidazole are recom-
mended. Because of increasing resistance of Escherichia
coli to fluoroquinolones, local population susceptibility
profiles and, if available, isolate susceptibility should be
always reviewed [103].
Selection of specific antimicrobial therapy for pediatric
patients with complicated intra-abdominal infection
should be based on the origin of infection (community
vs health care), severity of illness, and safety of the anti-
microbial agents in specific pediatric age groups. For
pediatric patients with complicated intra-abdominal
infection, ertapenem, meropenem, imipenem/cilastatin,
ticarcillin-clavulanate, and piperacillin-tazobactam as
single-agent therapy or Ceftriaxone, cefotaxime, cefe-
pime, ceftazidime, each in combination with metronida-
zole, gentamicin or tobramycin, each in combination
with metronidazole or clindamycin, and with or without
ampicillin are recommended [103].
Beta-lactam/beta-lactamase inhibitor combinations,
have been widely used in the last decade. Their in vitro
activity includes gram-positive (include Enterococci in
their spectrum), gram-negative and anaerobe organisms
[107,108].
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ticarcillin/clavulanate and ampicillin/sulbactam have
been used in the treatment of intra mild to moderate
intra-abdominal infections. Ampicillin-sulbactam is still
indicated for community infections of mild-to-moderate
severity [109], however the increasing resistance of
Enterobacteriaceae reported in the last decade could
compromise its clinical effectiveness [110].
Piperacillin/tazobactam is a beta-lactam/beta-lacta-
mase inhibitor combination with increased gram-nega-
tive spectrum and anti-pseudomonas activity.
Piperacillin/tazobactam retains in vitro activity against
broad-spectrum beta-lactamase-producing, many
extended-spectrum beta-lactamase-producing Entero-
bacteriaceae and many Pseudomonas isolates. It is still a
reliable option for the empiric treatment of high risk
intra-abdominal infections [111].
Carbapenems have a spectrum of antimicrobial activity
that includes Gram-positive (except resistant gram posi-
tive cocci) and Gram-negative aerobic and anaerobic
pathogens.
Group 1 carbapenems includes ertapenem, a once a
day carbapenem that shares the activity of imipenem
and meropenem against most species, including
extended-spectrum b-lactamase (ESBL)-producing
pathogens [112,113], but is not active against non-fer-
mentative gram negative and Enterococcus. Ertapenem is
particularly suitable for low risk community-acquired
intra-abdominal infections. Once-daily ertapenem is an
interesting option for the treatment of these infections.
Group 2 includes imipenem/cilastatin, meropenem
and doripenem, that share activity against non-fermen-
tative gram-negative bacilli and are particularly suitable
for severe infections.
Doripenem is a new 1-b-methyl carbapenem recently
approved by the Food and Drug Administration for the
treatment of complicated intra-abdominal infections and
complicated urinary tract infections. Doripenem simi-
larly to imipenem and meropenem, has a broad-spec-
trum activity against Gram-positive, Gram-negative, and
anaerobic bacteria [114,115]. Doripenem is more effec-
t i v e ,i nv i t r o ,t h a nm e r o p e n e ma n di m i p e n e ma g a i n s t
Pseudomonas aeruginosa [116,117].
Group 2 carbapenems are important options for the
empirical treatment of high risk intra-abdominal infec-
tions also in hospitalized patients.
In the past Cephalosporins have been often used in the
treatment of intra-abdominal infections. Cephalosporins
except, the second generation subgroup with activity
against Bacteroides spp (cefoxitin and cefotetan), do not
exhibit anti-anaerobic activity and must always be used
in combination with anti-anaerobic agents [118].
Second-generation cephalosporins are widely used in
surgical prophylaxis and trauma. They have been used
in the treatment of mild-to-moderate community-
acquired infections, but limitations in their spectra and
microbial resistance restrict their utility in complicated
intra-abdominal infections.
Among third generation cephalosporins both sub-
groups with poor activity against Pseudomonas aerugi-
nosa (cefotaxime, ceftriaxone, and ceftizoxime) and with
good activity against Pseudomonas aeruginosa (cefopera-
zone and ceftazidime) have been used in the treatment
of intra-abdominal infections in association with metro-
nidazole. Both cephalosporins acquired resistance in
enterobacteriaceae [119,120] and intrinsic resistance in
Enterococci [121] may limit cephalosporins use in high
risk intra-abdominal infections especially in healt-care
infections.
Cefepime is a ‘fourth-generation’ cephalosporin. It was
introduced into clinical practice in 1994 and is used in
association with metronidazole for the treatment of
severe infections [122]. Cefepime possesses higher in
vitro activity than other extended-spectrum cephalos-
porins against common Gram-negative and Gram-posi-
tive pathogens and may be effective, in association with
metronidazole, in high risk intra-abdominal infections
[103,123]. The results of a meta-analysis by Yahav et al.
[124] in 2007 indicated a potential increased mortality
in patients treated with cefepime compared with
patients treated with other b-lactam drugs. Caution in
the use of cefepime should be adopted until new evi-
dence on cefepime safety is available [125].
Fluoroquinolones have been widely used in the last
years for the treatment of intra-abdominal infections,
because of their excellent activity against aerobic Gram-
negative bacteria and tissue penetration. In addition all
the fluoroquinolones are rapidly and almost completely
absorbed from the gastrointestinal tract. Peak serum
concentrations obtained after oral administration are
very near those achieved with intravenous administra-
tion [126].
Quinolones do not exhibit potent antianaerobic activ-
ity and have been used in combination with other thera-
peutic antianaerobic agents. Many studies have proved
fluoroquinolones in association with metronidazole an
effective therapeutic option for the treatment of patients
with intra-abdominal infections since their discovery
[127]. The combination of ciprofloxacin/metronidazole
has been one of the most commonly used regimens for
the treatment of patients with severe complicated intra-
abdomianl infections in the last years. Ciprofloxacin is a
potential therapeutic option for the treatment of infec-
tions caused by Pseudomonas and ESBL producing
enterobacteriaceae; however, in recent years, the con-
sumption of ciprofloxacin has risen and ESBL-producing
isolates resistant to fluoroquinolones has increased over
time, initially in K. pneumoniae and later also in E. coli
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against Enterococci and staphylococci. Nowadays doubts
emerge about the advisability of using ciprofloxacin plus
metronidazole to treat severe intra-abdominal infections
in high risk patients.
Moxifloxacin has shown activity against a wide range
of aerobic Gram-positive and Gram-negative [129].
Compared with ciprofloxacin, moxifloxacin has
enhanced activity against Gram-positive bacteria with a
decrease in activity against Gram-negative bacteria
(Enterobacteriaceae and Pseudomonas species) [130].
Among quinolones moxifloxacin seems to be effective
also against Bacterioides fragilis, suggesting that it may
be effective for the treatment of low risk intra-abdom-
inal infections without antianaerobic agents [131-133].
Levofloxacin has a spectrum of activity similar to
moxifloxacin’s ,a n de v e ni fc o m p a r e dt om o x i f l o x a c i ni t
has no activity against anaerobic bacteria, less activity
against resistant Gram Positive bacteria [134], it has a
potential activity against Pseudomonas [135]. In associa-
tion with metronidazole it is effective for the treatment
of low risk intra-abdominal infections.
Aminoglycosides such as gentamicin, tobramycin and
amikacin are particularly active against aerobic Gram-
negative bacteria and act synergistically against certain
Gram-positive organisms. Gentamicin is the most com-
monly used aminoglycoside, but amikacin may be parti-
cularly effective against resistant organisms. They are
effective against Pseudomonas aeruginosa. Aminoglyco-
sides are not effective against anaerobic bacteria.
Because of ototoxicity and nephrotoxicity aminoglyco-
sides have not often been recommended for the routine
empiric treatment of community-acquired intra-abdom-
inal infections [103]. Aminoglycosides may be reserved
for patients with allergies to b-lactam agents and may
be selected for treatment of patients with health care-
associated intra-abdominal infection, depending on local
susceptibility patterns of nosocomial gram-negative
bacilli [103].
Aztreonam is a parenteral synthetic beta-lactam anti-
biotic and the first monobactam to be marketed.
Aztreonam exhibits potent and specific activity in vitro
against a wide spectrum of Gram-negative aerobic
pathogens including Pseudomonas aeruginosa.I th a sn o
useful activity against Gram-positive bacteria or anae-
robes, but has very broad spectrum against Gram-nega-
tive aerobes, including Pseudomonas aeruginosa [136].
In the treatment of complicated intra-abdominal infec-
tions it is not practical as a single agent since anaerobic
and Gram-positive bacteria are not susceptible to
aztreonam [137].
Tigecycline is the first representative of the glycylcy-
cline class of antibacterial agents to be marketed for
clinical use [138,139].
Tigecycline represents a new treatment option for com-
plicated intra-abdominal infections due to its favourable in
vitro activity against a wide variety of aerobic Gram-posi-
tive, (including multidrug-resistant pathogens such as
MRSA, VISA, VRSA, VRE) [140], Gram-negative (includ-
ing ESBL-producing strains of E. coli and Klebsiella)
[141,142] and anaerobic organisms. Tigecycline has no
activity in vitro against P. aeruginosa and P. mirabilis.
Tigecycline has showed also considerable, though not
universally consistent, antimicrobial activity against
MDR (including carbapenem-resistant) Acinetobacter
spp [143-145].
Tigecycline is recommended by IDSA guidelines for
empiric treatment of mild-to-moderate severity infec-
tions [103].
Tigecycline maintains satisfactory profiles of safety and
efficacy in treatment of multidrug resistant bacteria, in
complicated intra-abdominal infections. Judicious use of
antibiotics for multidrug resistant pathogens is impor-
tant to preserve their effectiveness, and tigecycline is
one of the few available compounds active against multi-
drug resistant strains. It may be more suitable to use
tigecycline for empiric or definitive treatment of patients
with high risk intra-abdominal infections. Combinations
with other broad-spectrum antibiotics may be suitable
in critically ill patients or in patients with health-care
infections known or suspected to be owing to Pseudo-
monas aeruginosa.
Adequate therapy
Adequate indications and duration of therapy are parti-
cularly important. Inadequate duration of treatment is
probably the main inappropriate use of antibiotics in
surgical practice and the intensive care unit. Antimicro-
bial therapy for established infections should be contin-
ued until normalization of clinical signs of infection
occurs, including normalization of temperature and
WBC count. If clinical signs and symptoms persist after
a reasonable course of antibiotic therapy, another infec-
tious cause should be sought rather than prolonging
antibiotic treatment for the initial infection.
Unnecessary broad coverage or prolonged therapy can
carry high costs, toxicities of therapy and Clostridium
difficile colitis superinfection. Clostridium difficile causes
15%-25% of all cases of antibiotic-associated diarrhea,
the severity of which ranges from mild diarrhea to ful-
minant pseudomembranous colitis [146].
Over the past years, some Authors have investigated
procalcitonin (PCT) to guide duration of antibiotic ther-
apy. Currently, procalcitonin (PCT) has emerged as a
laboratory variable that allows early differentiation
between SIRS and sepsis. It was recently been used to
guide antibiotic treatment in medical patients with pul-
monary diseases [147].
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tive trial to value the role of procalcitonin for guiding
antibiotic therapy in surgical intensive care patients.
They enrolled a total of 110 surgical intensive care
patients receiving antibiotic therapy after confirmed or
high-grade suspected infections. In 57 patients antibiotic
therapy was guided by daily PCT and clinical assessment
and adjusted accordingly. The control group comprised
53 patients with a standardized duration of antibiotic
therapy over eight days. In the PCT group the duration
of antibiotic therapy was significantly shorter than in
the control group without negative effects on clinical
outcome.
Inappropriate antibiotic therapy of intra-abdominal
infections may result in poor patient outcomes.
In order to value the association between inappropri-
ate antibiotic therapy and clinical outcomes for compli-
cated community-acquired intra-abdominal infections
Tellado et al. [149] reviewed patient records from Octo-
ber 1998 to August 2002 in 24 hospitals in Spain. They
classified initial empiric therapy as appropriate if all iso-
lates were sensitive to at least 1 of the antibiotics admi-
nistered. Inappropriate initial antibiotic therapy was
associated with a significantly higher rate of unsuccess-
ful outcomes including death, re-operation, re-hospitali-
zation or additional parental antibiotic therapies.
In 2008 Edelsberg et al. [150] explored the economic
consequences of failure of empiric therapy in antibiotic
therapy in hospitalized adults with complicated intra-
abdominal infection. Using a large U.S. multi-institu-
tional database, they identified all hospitalized adults
admitted between April 2003 and March 2004 with
cIAI, who had undergone laparotomy, laparoscopy or
percutaneous drainage and had received intravenous
antibiotics. Antibiotic failure was considered on the
basis of the need for reoperation or receipt of other
antibiotics postoperatively. Among 6,056 patients who
met the study entrance criteria, 22.4% failed initial anti-
biotic therapy. Failure of initial intravenous antibiotics
in hospitalized adults with cIAIs was associated with
longer hospitalization, higher hospital charges, and
higher mortality rate.
De escalation approach in critically ill patients
The rise in antibiotic resistance in the ICU poses serious
problems for the management of critically ill patients.
The choice of empiric antibiotic therapy can have a sig-
nificant impact on patient outcome when resistant
pathogens may be involved. Empiric antimicrobial ther-
apy for patients with severe sepsis or septic shock may
be ineffective if the responsible organism is not suscepti-
ble to available antibiotics. Therefore, attention has been
focused on the need for strategies to combat antibiotic
resistance in the ICU.
In critically ill patients a de escalation approach may
be recommended. For years antibiotic therapy has been
started with a basic agent and only once microbiological
culture results and susceptibility tests were available,
more potent compounds were used. The traditional
approach, however, may no longer be appropriate for
critically ill patients in the current era of increasing anti-
biotic resistance.
Rising resistance rates and better understanding of the
inflammatory process prompted some experts to advo-
cate initial therapy with broad-spectrum, initially in
severe pneumonias [151,152].
This two-stage approach of using aggressive initial
therapy followed by de-escalation allows serious infec-
tion to be treated immediately and effectively avoiding
antibiotic overuse, potential resistance and excessive
costs.
Multidrug-resistant pathogens
The threat of antimicrobial resistance has been identi-
fied as one of the major challenges in the management
of complicated intra-abdominal infections.
Over the past few decades, an increase of infections
caused by antibiotic-resistant pathogens, including
methicillin-resistant Staphylococcus aureus, vancomycin-
resistant Enterococcus species, carbapenem-resistant
Pseudomonas aeruginosa, extended-spectrum beta-lacta-
mase-producing Escherichia coli and Klebsiella spp., and
multidrug-resistant Acinetobacter spp., has been
observed, also in intra-abdominal infections.
Management of severe intra-abdominal infections
must always include a balance between optimizing
empirical therapy, which has been shown to improve
outcomes, and reducing unnecessary antimicrobial use.
Bacterial resistance is becoming a very important pro-
blem. Despite increasing antimicrobial resistance and
multi-drug resistance in clinical isolates, there are few
novel antimicrobial agents in development. Some broad-
spectrum agents maintain still satisfactory profiles of
safety and efficacy in treatment of multidrug resistant
bacteria in complicated intra-abdominal infections but
they must be used judiciously to preserve their effective-
ness against multidrug resistant pathogens.
Enterococcus
Enterococcus infections are difficult to treat because of
both intrinsic and acquired resistance to many
antibiotics.
Enterococci are intrinsically resistant to many penicil-
lins, and all cephalosporins with the possible exception
of ceftobiprole and ceftaroline, currently undergoing
clinical evaluation. Besides Enterococci have acquired
resistance to many other classes of antibiotics, to which
the organisms are not intrinsically resistant, including
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strains of E. faecalis are susceptible to certain penicillins,
carbapenems, and fluoroquinolones; however, virtually
all strains of E. faecium are resistant to these agents
[153].
Vancomycin-resistant Enterococci (VRE) infections
have bee associated with increased morbidity and mor-
tality [154,155]. Resistance of Enterococci to vancomycin
was reported in Europe in 1986 and the prevalence of
infections related to VRE has continued to increase
annually [156].
Many factors can increase the risk of colonization with
VRE. These include previous antibiotic therapy, the
number and duration of antibiotics received, prolonged
hospitalization, hospitalization in an intensive care unit
and concomitant serious illness [157].
Several antibiotics have been implicated for VRE
acquisition, but use of vancomycin and third-generation
cephalosporins have appeared to be associated most
commonly with the spread of VRE [158].
Against Vancomycin-resistant Enterococci (VRE) line-
zolid, tigecycline, quinupristin/dalfopristin, or daptomy-
cin should be considered.
Empirical treatment against Enterococci and has not
been generally recommended for patients who have
community-acquired intra-abdominal infections [103].
However Enterococci isolation may be a risk factor for
treatment failure and it has been suggested that if initial
antibiotic therapy does not cover for Enterococci,
patients may have an increased risk of postoperative
complications and death [159,160]. Recently Riché et al.
[161] published a prospective observational study invol-
ving 180 consecutive patients with secondary general-
ized peritonitis (community-acquired and postoperative)
which analyzed clinical and bacteriological factors asso-
ciated with the occurrence of shock and mortality in
patients with secondary generalized peritonitis. Fre-
quency of septic shock was 41% and overall mortality
rate was 19%. Patients with septic shock had a mortality
rate of 35%, versus 8% for patients without shock. Septic
shock occurrence and mortality rate were not different
between community-acquired and postoperative perito-
n i t i s .A g eo v e r6 5 ,t w oo rm o r em i c r o o r g a n i s m s ,o r
anaerobes in peritoneal fluid culture were independent
risk factors of shock. Intraperitoneal yeasts and Entero-
cocci were associated with septic shock in community-
acquired peritonitis. Their findings supported the dele-
terious role of Enterococcus species in peritoneal fluid,
reinforcing the need of prospective trials to evaluate sys-
tematic treatment against these microorganisms in
patients with secondary peritonitis.
Enterococcal infection should be suspected in patients
with post-operative or nosocomial infections, in patients
with recent exposure to broad-spectrum antimicrobial
agents especially cephalosporins, in immunocompro-
mised patients and in patients with valvular heart dis-
ease or prosthetic intravascular materials [103].
Expanded spectrum agents against enterocci should be
also recommended for these patients with severe sepsis
and septic shock in which a de escalation approach of
an initially broad antimicrobial regimen to scale when
definitive culture results are available [162,163].
For community-acquired biliary infection, antimicro-
bial activity against enterococci should be not required,
because the pathogenicity of enterococci has not been
demonstrated. For selected immunosuppressed patients,
particularly those with hepatic transplantation, entero-
coccal infections may be significant and require treat-
ment also for community-acquired biliary infection
[103].
Methicillin resistant Staphylococcus aureus
Methicillin resistant Staphylococcus aureus (MRSA) is
the other multiresistant Gram-positive nosocomial
pathogen that causes severe morbidity and mortality
worldwide.
Methicillin-resistant S. aureus (healthcare-acquired
MRSA; HA-MRSA) isolates have been a source of ser-
ious infections in hospitals since the 1960s and in the
period 1975 to 1991, the National Nosocomial Infection
Surveillance data showed that within all hospitals, there
was an increase from 2% to 29% in the proportion of
methicillin resistance among S aureus, and an increase
to 38% in those hospitalsw i t hm o r et h a n5 0 0b e d s
[164].
In recent years isolates of community-associated (CA-
MRSA) have been identified too [165].
The traditional antibiotic therapy for MRSA has
always been glycopeptides.
The widespread occurrence of MRSA induced an
inevitable increase of vancomycin and teicoplanin use,
causing a selective pressure to develop glycopeptides
resistance so that in 1997 the first vancomycin-inter-
mediate Staphylococcus aureus (VISA) was reported and
after some years the first vancomycin-resistent Staphylo-
coccus aureus (VRSA) was also documented [166].
Multiresistant Staphylococcus aureus diffusion high-
lights the importance of the development of new agents
for the appropriate treatment of infections where highly
resistant pathogens are suspected or known. The list of
antimicrobial agents with activity against MRSA is short,
including Quinupristin/dalfopristin, daptomycin, linezo-
lid and tigecicline. Recently resistances also to linezolid
were identified [167].
Empiric antimicrobial against MRSA should be pro-
vided to patients with health care-associated intra-
abdominal infections who are known to be colonized
with the organism or who are suspected of having an
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ment failure and significant antibiotic exposure [103].
Extended-spectrum b-lactamases (ESBLs) producing
Enterobacteriaceae
Over the past few years a notable increase in antibiotic
resistance among Gram-negative bacteria recovered
from hospitalized patients has been reported, especially
in critically ill patients [168].
During the last decade, the emergence of multidrug-
resistant (MDR) Gram-negative bacteria such as Pseudo-
monas aeruginosa, Acinetobacter baumannii, Stenotro-
phomonas maltophilia and extended-spectrum beta-
lactamase (ESBL) producing Enterobacteriaceae has
become a growing problem.
In the specific context of intra-abdominal infections,
resistance to b-lactams, mediated by extended-spectrum
b-lactamases (ESBLs) is a particular concern [169,170].
Acquired resistance to beta-lactams is mainly
mediated by extended-spectrum beta-lactamases (ESBLs)
that confer resistance to the penicillins, first-, second-,
and third-generation cephalosporins, and aztreonam,
a n da r ei n h i b i t e db yb - l a c t a mase inhibitors. Extended-
spectrum beta-lactamases (ESBLs) which are encoded by
genes that can be exchanged between bacteria. Beta-lac-
tamase genes are often associated with resistance deter-
minants to non-beta-lactam agents such as
aminoglycosides and fluoroquinolones, and strains pro-
ducing ESBLs often exhibit complex multidrug resistant
phenotypes and sometimes are panresistant [171,172].
Therefore, antibiotic options in the treatment of ESBL-
producing organisms are extremely limited. Carbape-
nems are the drugs of choice for treatment of infections
caused by ESBL-producing organisms in intra-abdom-
inal infections even if, use of carbapenems has been
associated with the emergence of carbapenem-resistant
bacterial species [173]. Tigecycline has substantial anti-
microbial activity against ESBL-producing Enterobacter-
iaceae but it merits further evaluation [141,142].
Data from SMART (Study for Monitoring Antimicro-
bial Resistance Trends) in the period 2005 to 2007 found
that the most frequently isolated organisms were Escheri-
chia coli, Klebsiella pneumoniae and Enterobacter cloa-
cae, of which 18% of E. coli and 26.2% of K. pneumoniae
were positive for extended-spectrum beta-lactamase
(ESBL) [174]. Overall, resistance among ESBL-producing
isolates increased during 2005-2007 and resistance rates
in 2007 were generally higher than data from previous
years. Carbapenems were the only agents that maintained
consistent activity against ESBL-producing isolates. In
such study Tigecycline was not tested.
High risk patients for ESBL producing organisms
infection are often seriously ill patients with prolonged
hospital stays in whom invasive medical devices are
present [119]. Other risk factors have been found and
include the presence of nasogastric tubes, gastrostomy
or jejunostomy tubes and arterial lines, administration
of total parenteral nutrition, recent surgery, hemodialy-
sis, decubitus ulcers, and poor nutritional status [119].
There is a strong relationship between antibiotics and
acquisition of an ESBL producing strain [119]. The anti-
biotic classes found to be associated with ESBL-produ-
cing organisms include especially cephalosporins and
quinolones.
Pseudomonas aeruginosa
Dramatic may be multidrug-resistant non fermenting
Gram-negative bacteria in ICUs. Pseudomonas aerugi-
nosa i sa m o n gt h el e a d i n gp a t h o g e n sc a u s i n gn o s o c o -
mial infections especially in the ICUs. P. aeruginosa
resistance depends on the bacteria’si n t r i n s i ca sw e l la s
remarkable ability to acquire antibiotic resistance
[175,176].
Antimicrobial agents with reliable anti-pseudomonas
activity that are commonly prescribed are limited to
antipseudomonas carbapenems, piperacillin/tazobactam,
ceftazidime, cefepime, fluoroquinolones, aminoglyco-
sides, aztreonam.
In the treatment of the most problematic multidrug
resistant Pseudomonas strains, the class of polymyxins,
represented by polymyxin B and polymyxin E (colistin),
has gained a principal role despite its high toxicity [177].
Data from SMART (Study for Monitoring Antimicro-
bial Resistance Trends) in the period 2005 to 2007 no
antimicrobial agent exhibited susceptibility of >90%
against Pseudomonas. The most active agents were ami-
kacin and piperacillin/tazobactam to which 86,5% of
Pseudomonas were susceptible.
No clear data or expert opinion are available, but P.
aeruginosa coverage is generally recommended in
patients with health-care intra-abdominal infections,
even if in some populations and communities, a rela-
tively and inexplicably high prevalence of Pseudomonas
aeruginosa, may be associated with community-acquired
appendicitis [178] and may impact the selection of
appropriate empiric antibiotic therapy [103].
Acinetobacter baumannii
Also Acinetobacter baumannii is increasingly reported
as the cause of nosocomial infections. Acinetobacter iso-
lates demonstrate increasing resistance to commonly
prescribed antimicrobials. Multidrug-resistant Acineto-
bacter baumannii is one of the most difficult healthcare-
associated infections to control and treat [179-181].
The management of A. baumannii infections is diffi-
cult, because of the increasing number of isolates exhi-
biting resistance to multiple classes of antibacterial
agents [182,183]. Agents potentially effective against A.
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kacin or gentamicin), tetracyclines (minocycline or dox-
ycycline) and sulbactam [184].
Data from TEST (The Tigecycline Evaluation and Sur-
veillance Trial) during 2004-2007 showed that the most
active agents against Acinetobacter spp. were tigecycline,
minocycline and Group 2 carbapenems [185].
Resistance to tigecycline and carbapenems makes mul-
tidrug-resistant Acinetobacter infections difficult to
treat. Colistin and polymyxin B have been used to treat
highly resistant Acinetobacter infections. The choice of
appropriate therapy is further complicated by the toxi-
city of colistin [186,187].
Acinetobacter isolates resistant to colistin and poly-
myxin B have also been reported [188]. Studies have
demonstrated in-vitro susceptibility of multidrug-resis-
tant Acinetobacter to various synergistic combinations
of antimicrobials including carbapenems, colistin, rifam-
pin, ampicillin-sulbactam and tigecycline [189,190].
Bacteroides fragilis
The Bacteroides fragilis group is a predominant compo-
nent of the normal bacterial flora of the gastrointestinal
tract. These bacteria are frequently isolated from mixed
aerobic-anaerobic infections, such as intra-abdominal
infections.
The increasing resistance to antimicrobial agents
among anaerobic pathogens has been a global problem
in the last years. Susceptibility to antibiotics varies con-
siderably among the species of the group.
Clinically, Bacteroides species have exhibited increas-
ing resistance to many antibiotics. Resistance to the
most active drugs, such as imipenem, piperacillin-tazo-
bactam, and metronidazole, has been found in occa-
sional strains [191,192].
Most clinical laboratories do not routinely determine the
species of the organism or test the susceptibilities of any
anaerobic isolates, including those in the B. fragilis group,
because of technical difficulties surrounding Bacteroides
susceptibility testing. Consequently, the treatment of anae-
robic infections is selected empirically, based on published
reports on patterns of susceptibility [193].
A multicenter study by Aldridge et al. [194] surveyed
the susceptibilities of 556 clinical anaerobic isolates, pre-
dominantly intra-abdominal, from four large medical
centers. Piperacillin-tazobactam was the only antimicro-
bial agent to which all the isolates were susceptible.
Similarly, imipenem, meropenem, and metronidazole
were highly active (resistance, <0.5%), whereas the low-
est susceptibility rates were noted for ciprofloxacin, and
clindamycin.
A recent multicenter study by Snydman et al. [193]
determined the susceptibility trends for the species of
the Bacteroides fragilis group against various antibiotics
from 1997 to 2004 by using data for 5,225 isolates
referred by 10 medical centers in the United States.
Resistance to carbapenems was rarely seen in this study
(<1.5%). The trends in resistance to piperacillin-tazobac-
tam, ampicillin-sulbactam, and cefoxitin were species
dependent. Resistance of B. fragilis, to clindamycin
increased significantly, similar results were seen for
moxifloxacin. Resistance rates for tigecycline were low
and stable during the 5-year period during which this
agent was studied.
Candida
In the last years there has been a significant increase in
the incidence of invasive infections due to Candida spe-
cies. Candida intra-abdominal infections are associated
with poor prognosis [195]. Thirty to forty percent of
patients with recurrent gastrointestinal perforation/ana-
stomotic leakage develop intra-abdominal invasive can-
didiasis [196].
The most frequently implicated risk factors include
the use of broad-spectrum antibacterial agents, use of
central venous catheters, receipt of parenteral nutrition,
receipt of renal replacement therapy by patients in
ICUs, neutropenia, and receipt of immunosuppressive
agents (including glucocorticosteroids, chemotherapeutic
agents, and immunomodulators). Patients with health
care-associated intra-abdominal infection are at higher
risk of Candida peritonitis, particularly patients with
recurrent gastrointestinal perforations and surgically
treated pancreatic infection.
Empiric antifungal therapy with fluconazole may
decrease the incidence of Candida peritonitis in high-
risk patients [103].
Fluconazole, is recommended as initial therapy [197].
An echinocandin (Caspofungin, Anidulafungin, or Mica-
fungin) is preferred for patients with recent azole expo-
sure, patients with moderately severe to severe illness,
or patients who are at high risk of infection due to C.
glabrata or C. krusei.
Avoiding unnecessary antibiotics and optimizing the
administration of antimicrobial agents will help to
improve patient outcomes and minimize further pres-
sures for resistance.
Several strategies aim at achieving optimal use of anti-
microbial agents, such as guidelines or protocols,
restricting the hospital formulary, combining antibiotic
therapy, antibiotic rotation, area-specific antimicrobial
therapy, antimicrobial de-escalation and infections con-
trols [198], but it is important that surgeons know anti-
biotic administration minimal requirements, such as
antibiotics spectrum of activity and drug effective dos-
ing. Without these minimal requirements surgeons will
increase the likelihood of treatment failures and antibio-
tic resistance.
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Complicated intra-abdominal infections are an impor-
tant cause of morbidity and are frequently associated
with a poor prognosis.
Despite advances in diagnosis, surgery, antimicrobial
therapy mortality associated with complicated intra-
abdominal infections remains still unacceptably high.
Early adequate source control remains the cornerstone
of intra-abdominal infection management. Early control
of the septic source can be achieved either by nonopera-
tive or operative means. Timing and adequacy of source
control is the most important issue in the management
of intra-abdominal infections, because an inadequate
and late operation may have a negative effect on
outcome.
Recent advances in interventional and more aggressive
techniques are debated and are not validated by limited
prospective trials.
Concomitant adequate empiric antimicrobial therapy
further influences patients morbidity and mortality.
Inappropriate antibiotic therapy of intra-abdominal
infections may result in poor patient outcome and the
selection of an appropriate agent is a real challenge
because of the emerging resistance of target organisms
to commonly prescribed antibiotics.
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